BioHarvest Sciences Q2 Earnings Call Highlights
BioHarvest Sciences (NASDAQ:BHST) reported Q2 gross profit of $5.1M and a net loss of $3.7M ($0.17/share). Cash was $16.2M at June 30. 2026 revenue guidance was cut to $37M-$40M and EBITDA loss to $3M-$5M. Management tightened CDMO revenue to $4M-$5M and reduced VINIA outlook to $33M-$35M.
How this was made
The 30-second read
Why it matters
Traders can reprice BHST based on the guidance reset: lower 2026 revenue range, a revised EBITDA loss outlook, and a tighter CDMO revenue band, alongside a stated intent to reach consolidated EBITDA breakeven in 2027 while avoiding equity-based financing.
Market read
Fresh guidance and strategy changes (revenue, EBITDA loss, CDMO range, VINIA outlook) are the main decision inputs for BHST positioning after the Q2 call.
What to watch
VINIA price increase (up to 20% for new subscribers) and the saffron cell bank milestone may offset some revenue softness, but the article does not quantify their near-term financial impact.
Background
The piece summarizes BioHarvest Sciences’ Q2 earnings call, focusing on updated 2026 guidance, CDMO strategy, VINIA spending shifts, and cash position.
Ticker impact
BioHarvest cut 2026 revenue guidance to $37M-$40M and tightened CDMO revenue to $4M-$5M, signaling slower growth and a narrower CDMO push.
Bias toward downside or higher volatility until investors underwrite the revised revenue and cash plan.
The article provides multiple fresh, decision-relevant guidance changes (revenue, EBITDA loss range, CDMO range) plus cash balance deterioration, which typically pressures microcap biotech valuations.
Market effects
Reinforces a broader CDMO and plant-based ingredient theme where investors reward faster path-to-manufacturing revenue and penalize broad, exploratory pipelines.
Limited, as the disclosure is company-specific to a US-listed microcap.
Low, unless the saffron cell bank and sweetener collaboration materially change competitive positioning in plant-based ingredients.
Counterpoint
The company’s cash balance jump and tighter CDMO focus could improve execution quality, making the revised ranges more achievable and reducing dilution risk.
Key entities
- companyBioHarvest Sciences
NASDAQ-listed plant-based active ingredient developer and CDMO operator; subject of the earnings call highlights.
- productVINIA
Direct-to-consumer offering whose spending and revenue outlook were revised.
- partnerTate & Lyle
Sweetener collaboration expanded to additional plant-based sweetener molecules.
